Faculty Appointments
Associate Professor of Medicine
Education
Ph.D., Molecular Cell Biology, Washington University, Saint Louis, MissouriM.D., Medicine, Washington University, Saint Louis, MissouriB.A., Chemistry, Johns Hopkins University, Baltimore, Maryland
Office Address
ADMIN OFFICE ADDRESS:
2220 Pierce Avenue South
777 Preston Research Building
Nashville, TN 37232
2220 Pierce Avenue South
777 Preston Research Building
Nashville, TN 37232
Research Keywords
Lung Cancer, EGFR , ALK, kinase fusions, acquired resistance, targeted therapies, tyrosine kinase inhibitors (TKIs), genomics, EGFR mutation, Small Cell Lung Cancer, Liquid Biopsies, Structural Biology, Precision Medicine
Clinical Research Keywords
Medical oncology,
Lung cancer
Publications
Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL. An Acquired HER2(T798I) Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discov [print-electronic]. 2017 Jun; 7(6): 575-85. PMID: 28274957, PMCID: PMC5457707, PII: 2159-8290.CD-16-1431, DOI: 10.1158/2159-8290.CD-16-1431, ISSN: 2159-8290.
Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, Ye F, Kulick A, de Stanchina E, McEwen R, Ladanyi M, Cross D, Pao W, Lovly CM. SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Res [print-electronic]. 2017 Jun 6/1/2017; 77(11): 2990-3000. PMID: 28416483, PMCID: PMC5467531, PII: 0008-5472.CAN-16-2300, DOI: 10.1158/0008-5472.CAN-16-2300, ISSN: 1538-7445.
Lovly CM, Iyengar P, Gainor JF. Managing Resistance to EFGR- and ALK-Targeted Therapies. Am Soc Clin Oncol Educ Book. 2017; 37: 607-18. PMID: 28561721, PII: 176251, DOI: 10.14694/EDBK_176251, ISSN: 1548-8756.
Horn L, Wakelee H, Reckamp KL, Blumenschein G, Infante JR, Carter CA, Waqar SN, Neal JW, Harrow K, Gockerman JP, Dukart G, Liang C, Gibbons JL, Hernandez J, Newman-Eerkes T, Lim L, Lovly CM. MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology. J Thorac Oncol [print-electronic]. 2016 Nov; 11(11S): S256-S257. PMID: 27969449, PII: S1556-0864(16)30966-2, DOI: 10.1016/j.jtho.2016.09.017, ISSN: 1556-1380.
Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller VA, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunol Res [print-electronic]. 2016 Nov; 4(11): 959-67. PMID: 27671167, PMCID: PMC5134329, PII: 2326-6066.CIR-16-0143, DOI: 10.1158/2326-6066.CIR-16-0143, ISSN: 2326-6074.
Qiao H, Lovly CM. Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer. Cancer Discov. 2016 Oct; 6(10): 1084-6. PMID: 27698100, PMCID: PMC5117458, PII: 6/10/1084, DOI: 10.1158/2159-8290.CD-16-0910, ISSN: 2159-8290.
Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, Schildhaus HU, Fassunke J, Ihle MA, Pasternack H, Heydt C, Becker C, Altmüller J, Ji H, Müller C, Florin A, Heuckmann JM, Nuernberg P, Ansén S, Heukamp LC, Berg J, Pao W, Peifer M, Buettner R, Wolf J, Thomas RK, Sos ML. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clin. Cancer Res [print-electronic]. 2016 Oct 10/1/2016; 22(19): 4837-47. PMID: 27252416, PII: 1078-0432.CCR-15-1915, DOI: 10.1158/1078-0432.CCR-15-1915, ISSN: 1078-0432.
Leal T, Wakelee H, Infante J, Blumenschein G, Reckamp K, Carter C, Waqar S, Gockerman J, Lovly C, Dukart G, Harrow K, Liang C, Gibbons J, Horn L. P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC: Track: Advanced NSCLC. J Thorac Oncol [print-electronic]. 2016 Oct; 11(10S): S209-S210. PMID: 27676529, PII: S1556-0864(16)30775-4, DOI: 10.1016/j.jtho.2016.08.066, ISSN: 1556-1380.
Leal T, Wakelee H, Infante J, Blumenschein G, Reckamp K, Carter C, Waqar S, Gockerman J, Lovly C, Dukart G, Harrow K, Liang C, Gibbons J, Horn L. PD2.02 (also presented as P1.44): Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients With ALK+ NSCLC. J Thorac Oncol [print-electronic]. 2016 Oct; 11(10S): S176-S177. PMID: 27676483, PII: S1556-0864(16)30726-2, DOI: 10.1016/j.jtho.2016.08.017, ISSN: 1556-1380.
Dragani TA, Castells A, Kulasingam V, Diamandis EP, Earl H, Iams WT, Lovly CM, Sedelaar JP, Schalken JA. Major milestones in translational oncology [editorial]. BMC Med. 2016 Jul 7/28/2016; 14(1): 110. PMID: 27469586, PMCID: PMC4964079, PII: 10.1186/s12916-016-0654-y, DOI: 10.1186/s12916-016-0654-y, ISSN: 1741-7015.
Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, Vavalà T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM. EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Cancer Discov [print-electronic]. 2016 Jun; 6(6): 601-11. PMID: 27102076, PMCID: PMC4893907, PII: 2159-8290.CD-16-0075, DOI: 10.1158/2159-8290.CD-16-0075, ISSN: 2159-8290.
Johnson DB, Lovly CM, Sullivan RJ, Carvajal RD, Sosman JA. Melanoma driver mutations and immune therapy. Oncoimmunology. 2016 May; 5(5): e1051299. PMID: 27467925, PMCID: PMC4910708, PII: 1051299, DOI: 10.1080/2162402X.2015.1051299, ISSN: 2162-4011.
Taylor AD, Micheel CM, Anderson IA, Levy MA, Lovly CM. The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome. Transl Oncol. 2016 Apr; 9(2): 163-5. PMID: 27084433, PMCID: PMC4833964, PII: S1936-5233(16)30021-3, DOI: 10.1016/j.tranon.2016.03.001, ISSN: 1936-5233.
Hames ML, Chen H, Iams W, Aston J, Lovly CM, Horn L. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer¿. Lung Cancer [print-electronic]. 2016 Feb; 92: 29-34. PMID: 26775593, PMCID: PMC4874190, PII: S0169-5002(15)30100-8, DOI: 10.1016/j.lungcan.2015.11.004, ISSN: 1872-8332.
Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016 Jan 1/29/2016; 7: 10582. PMID: 26822383, PMCID: PMC4740184, PII: ncomms10582, DOI: 10.1038/ncomms10582, ISSN: 2041-1723.
Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Res [print-electronic]. 2016 Jan 1/15/2016; 76(2): 305-18. PMID: 26744526, PMCID: PMC4715957, PII: 0008-5472.CAN-15-0717, DOI: 10.1158/0008-5472.CAN-15-0717, ISSN: 1538-7445.
Kusnoor SV, Koonce TY, Levy MA, Lovly CM, Naylor HM, Anderson IA, Micheel CM, Chen SC, Ye F, Giuse NB. My Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information. AMIA Jt Summits Transl Sci Proc. 2016; 2016: 112-21. PMID: 27570660, PMCID: PMC5001739, ISSN: 2153-4063.
Lovly CM, Salama AK, Salgia R. Tumor Heterogeneity and Therapeutic Resistance. Am Soc Clin Oncol Educ Book. 2016; 35: e585-93. PMID: 27249771, PII: 158808, DOI: 10.14694/EDBK_158808, ISSN: 1548-8756.
Giuse NB, Kusnoor SV, Koonce TY, Naylor HM, Chen SC, Blasingame MN, Anderson IA, Micheel CM, Levy MA, Ye F, Lovly CM. Guiding Oncology Patients Through the Maze of Precision Medicine. J Health Commun. 2016; 21 Suppl 1: 5-17. PMID: 27043753, PMCID: PMC4910693, DOI: 10.1080/10810730.2015.1131772, ISSN: 1087-0415.
Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J, Lovly CM. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Cancer Discov [print-electronic]. 2015 Nov; 5(11): 1155-63. PMID: 26286086, PMCID: PMC4631701, PII: 2159-8290.CD-15-0654, DOI: 10.1158/2159-8290.CD-15-0654, ISSN: 2159-8290.
Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. J. Clin. Oncol [print-electronic]. 2015 Oct 10/5/2015; PMID: 26438117, PII: JCO.2015.62.0138, DOI: 10.1200/JCO.2015.62.0138, ISSN: 1527-7755.
Iams WT, Lovly CM. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade. Clin. Cancer Res. 2015 Oct 10/1/2015; 21(19): 4270-7. PMID: 26429980, PMCID: PMC4593065, PII: 21/19/4270, DOI: 10.1158/1078-0432.CCR-14-2518, ISSN: 1078-0432.
Iams WT, Lovly CM. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. Cancer J. 2015 Sep; 21(5): 378-82. PMID: 26389762, PII: 00130404-201509000-00005, DOI: 10.1097/PPO.0000000000000142, ISSN: 1540-336X.
Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat. Med [print-electronic]. 2015 Sep; 21(9): 1038-47. PMID: 26301689, PII: nm.3930, DOI: 10.1038/nm.3930, ISSN: 1546-170X.
Ichihara E, Lovly CM. Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer. Cancer Discov. 2015 Jul; 5(7): 694-6. PMID: 26152920, PMCID: PMC4499857, PII: 5/7/694, DOI: 10.1158/2159-8290.CD-15-0616, ISSN: 2159-8290.
Meador CB, Lovly CM. Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors. Nat. Med. 2015 Jul; 21(7): 663-5. PMID: 26151324, PII: nm.3899, DOI: 10.1038/nm.3899, ISSN: 1546-170X.
Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin. Cancer Res. 2015 May 5/15/2015; 21(10): 2227-35. PMID: 25979929, PMCID: PMC4435823, PII: 21/10/2227, DOI: 10.1158/1078-0432.CCR-14-2791, ISSN: 1078-0432.
Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Cancer Immunol Res [print-electronic]. 2015 May; 3(5): 464-9. PMID: 25649350, PMCID: PMC4420706, PII: 2326-6066.CIR-14-0217, DOI: 10.1158/2326-6066.CIR-14-0217, ISSN: 2326-6074.
Hornick JL, Sholl LM, Dal Cin P, Childress MA, Lovly CM. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. Mod. Pathol [print-electronic]. 2015 May; 28(5): 732-9. PMID: 25612511, PII: modpathol2014165, DOI: 10.1038/modpathol.2014.165, ISSN: 1530-0285.
Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M. MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. Clin. Cancer Res [print-electronic]. 2015 Apr 4/15/2015; 21(8): 1935-43. PMID: 25351745, PMCID: PMC4401580, PII: 1078-0432.CCR-14-2124, DOI: 10.1158/1078-0432.CCR-14-2124, ISSN: 1078-0432.
Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res. 2015 Mar; 3(3): 288-95. PMID: 25736262, PMCID: PMC4351797, PII: 3/3/288, DOI: 10.1158/2326-6066.CIR-14-0207, ISSN: 2326-6074.
Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol. 2015 Mar; 10(3): 431-7. PMID: 25415430, PMCID: PMC4479120, DOI: 10.1097/JTO.0000000000000432, ISSN: 1556-1380.
Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, Lovly CM, Cross DA, Pao W. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. Mol. Cancer Ther [print-electronic]. 2015 Feb; 14(2): 542-52. PMID: 25477325, PMCID: PMC4338015, PII: 1535-7163.MCT-14-0723, DOI: 10.1158/1535-7163.MCT-14-0723, ISSN: 1538-8514.
Lovly CM. Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. Am Soc Clin Oncol Educ Book. 2015; e165-73. PMID: 25993168, PII: 0011500e165, DOI: 10.14694/EdBook_AM.2015.35.e165, ISSN: 1548-8756.
Yu HA, Riely GJ, Lovly CM. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin. Cancer Res [print-electronic]. 2014 Dec 12/1/2014; 20(23): 5898-907. PMID: 25303979, PMCID: PMC4253858, PII: 1078-0432.CCR-13-2437, DOI: 10.1158/1078-0432.CCR-13-2437, ISSN: 1078-0432.
Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. J Natl Compr Canc Netw. 2014 Nov; 12(11): 1629-49. PMID: 25361808, PII: 12/11/1629, ISSN: 1540-1413.
Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretic L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat. Med [print-electronic]. 2014 Sep; 20(9): 1027-34. PMID: 25173427, PMCID: PMC4159407, PII: nm.3667, DOI: 10.1038/nm.3667, ISSN: 1546-170X.
Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, Chung CT, Borinstein SC, Ross JS, Stephens PJ, Miller VA, Coffin CM. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov [print-electronic]. 2014 Aug; 4(8): 889-95. PMID: 24875859, PMCID: PMC4125481, PII: 2159-8290.CD-14-0377, DOI: 10.1158/2159-8290.CD-14-0377, ISSN: 2159-8290.
Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin. Cancer Res. 2014 May 5/1/2014; 20(9): 2249-56. PMID: 24789032, PMCID: PMC4029617, PII: 20/9/2249, DOI: 10.1158/1078-0432.CCR-13-1610, ISSN: 1078-0432.
Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin. Cancer Res [print-electronic]. 2014 May 5/1/2014; 20(9): 2264-75. PMID: 24599935, PMCID: PMC4008689, PII: 1078-0432.CCR-13-1591, DOI: 10.1158/1078-0432.CCR-13-1591, ISSN: 1078-0432.
Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretic L, Seidel D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M, Ansén S, Stoelben E, Wright GM, Russell P, Wainer Z, Solomon B, Field JK, Hyde R, Davies MP, Heukamp LC, Petersen I, Perner S, Lovly CM, Cappuzzo F, Travis WD, Wolf J, Vingron M, Brambilla E, Haas SA, Buettner R, Thomas RK. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun. 2014; 5: 3518. PMID: 24670920, PMCID: PMC4132974, PII: ncomms4518, DOI: 10.1038/ncomms4518, ISSN: 2041-1723.
Lammers PE, Lovly CM, Horn L. A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. J Natl Compr Canc Netw. 2014 Jan; 12(1): 6-11; quiz 11. PMID: 24453288, PMCID: PMC4151469, PII: 12/1/6, ISSN: 1540-1413.
Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA, Pao W. Characteristics of lung cancers harboring NRAS mutations. Clin. Cancer Res [print-electronic]. 2013 May 5/1/2013; 19(9): 2584-91. PMID: 23515407, PMCID: PMC3643999, PII: 1078-0432.CCR-12-3173, DOI: 10.1158/1078-0432.CCR-12-3173, ISSN: 1078-0432.
Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov [print-electronic]. 2013 Apr; 3(4): 430-43. PMID: 23533265, PMCID: PMC4086149, PII: 2159-8290.CD-12-0440, DOI: 10.1158/2159-8290.CD-12-0440, ISSN: 2159-8290.
Baikadi M, Lovly C, Horn L, Reckamp KL, Noonan K, Laskin J, Morris GJ. A 75-year-old man with progressive bronchioalveolar carcinoma. Semin. Oncol. 2013 Feb; 40(1): e1-8. PMID: 23391120, PII: S0093-7754(12)00203-5, DOI: 10.1053/j.seminoncol.2012.11.004, ISSN: 1532-8708.
Lovly CM, Horn L. Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC. Curr Treat Options Oncol. 2012 Dec; 13(4): 516-26. PMID: 22833206, DOI: 10.1007/s11864-012-0204-6, ISSN: 1534-6277.
Horn L, Lovly C. Update on HER1-3 in advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5): S369-71. PMID: 23160321, PII: 01243894-201212005-00003, DOI: 10.1097/JTO.0b013e31826defaa, ISSN: 1556-1380.
Levy MA, Lovly CM, Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res [print-electronic]. 2012 Nov; 22(11): 2101-8. PMID: 23019146, PMCID: PMC3483539, PII: gr.131128.111, DOI: 10.1101/gr.131128.111, ISSN: 1549-5469.
Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, Küppers R, Thomas RK. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin. Cancer Res [print-electronic]. 2012 Sep 9/1/2012; 18(17): 4682-90. PMID: 22912387, PII: 1078-0432.CCR-11-3260, DOI: 10.1158/1078-0432.CCR-11-3260, ISSN: 1078-0432.
Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol [print-electronic]. 2012 Mar 3/10/2012; 30(8): 863-70. PMID: 22215748, PMCID: PMC3295572, PII: JCO.2011.35.6345, DOI: 10.1200/JCO.2011.35.6345, ISSN: 1527-7755.
Lovly CM, Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med. 2012 Feb 2/8/2012; 4(120): 120ps2. PMID: 22323827, PII: 4/120/120ps2, DOI: 10.1126/scitranslmed.3003728, ISSN: 1946-6242.
Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE [print-electronic]. 2012; 7(4): e35309. PMID: 22536370, PMCID: PMC3335021, PII: PONE-D-12-03589, DOI: 10.1371/journal.pone.0035309, ISSN: 1932-6203.
Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, Rauh D, Pao W, Thomas RK. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin. Cancer Res [print-electronic]. 2011 Dec 12/1/2011; 17(23): 7394-401. PMID: 21948233, PMCID: PMC3382103, PII: 1078-0432.CCR-11-1648, DOI: 10.1158/1078-0432.CCR-11-1648, ISSN: 1078-0432.
Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res [print-electronic]. 2011 Jul 7/15/2011; 71(14): 4920-31. PMID: 21613408, PMCID: PMC3138877, PII: 0008-5472.CAN-10-3879, DOI: 10.1158/0008-5472.CAN-10-3879, ISSN: 1538-7445.
Lovly CM, Carbone DP. Lung cancer in 2010: One size does not fit all. Nat Rev Clin Oncol. 2011 Feb; 8(2): 68-70. PMID: 21278771, PII: nrclinonc.2010.224, DOI: 10.1038/nrclinonc.2010.224, ISSN: 1759-4782.
Lovly CM, Yan L, Ryan CE, Takada S, Piwnica-Worms H. Regulation of Chk2 ubiquitination and signaling through autophosphorylation of serine 379. Mol. Cell. Biol [print-electronic]. 2008 Oct; 28(19): 5874-85. PMID: 18644861, PMCID: PMC2547006, PII: MCB.00821-08, DOI: 10.1128/MCB.00821-08, ISSN: 1098-5549.
King JB, Gross J, Lovly CM, Piwnica-Worms H, Townsend RR. Identification of protein phosphorylation sites within Ser/Thr-rich cluster domains using site-directed mutagenesis and hybrid linear quadrupole ion trap Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun. Mass Spectrom. 2007; 21(21): 3443-51. PMID: 17918214, DOI: 10.1002/rcm.3223, ISSN: 0951-4198.
Bernal-Mizrachi L, Lovly CM, Ratner L. The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2006 Jun 6/13/2006; 103(24): 9220-5. PMID: 16751281, PMCID: PMC1482593, PII: 0507809103, DOI: 10.1073/pnas.0507809103, ISSN: 0027-8424.
King JB, Gross J, Lovly CM, Rohrs H, Piwnica-Worms H, Townsend RR. Accurate mass-driven analysis for the characterization of protein phosphorylation. Study of the human Chk2 protein kinase. Anal. Chem. 2006 Apr 4/1/2006; 78(7): 2171-81. PMID: 16579595, DOI: 10.1021/ac051520l, ISSN: 0003-2700.
Schwarz JK, Lovly CM, Piwnica-Worms H. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol. Cancer Res. 2003 Jun; 1(8): 598-609. PMID: 12805407, ISSN: 1541-7786.
Graves PR, Lovly CM, Uy GL, Piwnica-Worms H. Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene. 2001 Apr 4/5/2001; 20(15): 1839-51. PMID: 11313932, DOI: 10.1038/sj.onc.1204259, ISSN: 0950-9232.
Morgan SE, Lovly C, Pandita TK, Shiloh Y, Kastan MB. Fragments of ATM which have dominant-negative or complementing activity. Mol. Cell. Biol. 1997 Apr; 17(4): 2020-9. PMID: 9121450, PMCID: PMC232049, ISSN: 0270-7306.
Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, Ye F, Kulick A, de Stanchina E, McEwen R, Ladanyi M, Cross D, Pao W, Lovly CM. SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Res [print-electronic]. 2017 Jun 6/1/2017; 77(11): 2990-3000. PMID: 28416483, PMCID: PMC5467531, PII: 0008-5472.CAN-16-2300, DOI: 10.1158/0008-5472.CAN-16-2300, ISSN: 1538-7445.
Lovly CM, Iyengar P, Gainor JF. Managing Resistance to EFGR- and ALK-Targeted Therapies. Am Soc Clin Oncol Educ Book. 2017; 37: 607-18. PMID: 28561721, PII: 176251, DOI: 10.14694/EDBK_176251, ISSN: 1548-8756.
Horn L, Wakelee H, Reckamp KL, Blumenschein G, Infante JR, Carter CA, Waqar SN, Neal JW, Harrow K, Gockerman JP, Dukart G, Liang C, Gibbons JL, Hernandez J, Newman-Eerkes T, Lim L, Lovly CM. MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology. J Thorac Oncol [print-electronic]. 2016 Nov; 11(11S): S256-S257. PMID: 27969449, PII: S1556-0864(16)30966-2, DOI: 10.1016/j.jtho.2016.09.017, ISSN: 1556-1380.
Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller VA, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunol Res [print-electronic]. 2016 Nov; 4(11): 959-67. PMID: 27671167, PMCID: PMC5134329, PII: 2326-6066.CIR-16-0143, DOI: 10.1158/2326-6066.CIR-16-0143, ISSN: 2326-6074.
Qiao H, Lovly CM. Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer. Cancer Discov. 2016 Oct; 6(10): 1084-6. PMID: 27698100, PMCID: PMC5117458, PII: 6/10/1084, DOI: 10.1158/2159-8290.CD-16-0910, ISSN: 2159-8290.
Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, Schildhaus HU, Fassunke J, Ihle MA, Pasternack H, Heydt C, Becker C, Altmüller J, Ji H, Müller C, Florin A, Heuckmann JM, Nuernberg P, Ansén S, Heukamp LC, Berg J, Pao W, Peifer M, Buettner R, Wolf J, Thomas RK, Sos ML. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clin. Cancer Res [print-electronic]. 2016 Oct 10/1/2016; 22(19): 4837-47. PMID: 27252416, PII: 1078-0432.CCR-15-1915, DOI: 10.1158/1078-0432.CCR-15-1915, ISSN: 1078-0432.
Leal T, Wakelee H, Infante J, Blumenschein G, Reckamp K, Carter C, Waqar S, Gockerman J, Lovly C, Dukart G, Harrow K, Liang C, Gibbons J, Horn L. P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC: Track: Advanced NSCLC. J Thorac Oncol [print-electronic]. 2016 Oct; 11(10S): S209-S210. PMID: 27676529, PII: S1556-0864(16)30775-4, DOI: 10.1016/j.jtho.2016.08.066, ISSN: 1556-1380.
Leal T, Wakelee H, Infante J, Blumenschein G, Reckamp K, Carter C, Waqar S, Gockerman J, Lovly C, Dukart G, Harrow K, Liang C, Gibbons J, Horn L. PD2.02 (also presented as P1.44): Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients With ALK+ NSCLC. J Thorac Oncol [print-electronic]. 2016 Oct; 11(10S): S176-S177. PMID: 27676483, PII: S1556-0864(16)30726-2, DOI: 10.1016/j.jtho.2016.08.017, ISSN: 1556-1380.
Dragani TA, Castells A, Kulasingam V, Diamandis EP, Earl H, Iams WT, Lovly CM, Sedelaar JP, Schalken JA. Major milestones in translational oncology [editorial]. BMC Med. 2016 Jul 7/28/2016; 14(1): 110. PMID: 27469586, PMCID: PMC4964079, PII: 10.1186/s12916-016-0654-y, DOI: 10.1186/s12916-016-0654-y, ISSN: 1741-7015.
Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, Vavalà T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM. EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Cancer Discov [print-electronic]. 2016 Jun; 6(6): 601-11. PMID: 27102076, PMCID: PMC4893907, PII: 2159-8290.CD-16-0075, DOI: 10.1158/2159-8290.CD-16-0075, ISSN: 2159-8290.
Johnson DB, Lovly CM, Sullivan RJ, Carvajal RD, Sosman JA. Melanoma driver mutations and immune therapy. Oncoimmunology. 2016 May; 5(5): e1051299. PMID: 27467925, PMCID: PMC4910708, PII: 1051299, DOI: 10.1080/2162402X.2015.1051299, ISSN: 2162-4011.
Taylor AD, Micheel CM, Anderson IA, Levy MA, Lovly CM. The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome. Transl Oncol. 2016 Apr; 9(2): 163-5. PMID: 27084433, PMCID: PMC4833964, PII: S1936-5233(16)30021-3, DOI: 10.1016/j.tranon.2016.03.001, ISSN: 1936-5233.
Hames ML, Chen H, Iams W, Aston J, Lovly CM, Horn L. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer¿. Lung Cancer [print-electronic]. 2016 Feb; 92: 29-34. PMID: 26775593, PMCID: PMC4874190, PII: S0169-5002(15)30100-8, DOI: 10.1016/j.lungcan.2015.11.004, ISSN: 1872-8332.
Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016 Jan 1/29/2016; 7: 10582. PMID: 26822383, PMCID: PMC4740184, PII: ncomms10582, DOI: 10.1038/ncomms10582, ISSN: 2041-1723.
Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Res [print-electronic]. 2016 Jan 1/15/2016; 76(2): 305-18. PMID: 26744526, PMCID: PMC4715957, PII: 0008-5472.CAN-15-0717, DOI: 10.1158/0008-5472.CAN-15-0717, ISSN: 1538-7445.
Kusnoor SV, Koonce TY, Levy MA, Lovly CM, Naylor HM, Anderson IA, Micheel CM, Chen SC, Ye F, Giuse NB. My Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information. AMIA Jt Summits Transl Sci Proc. 2016; 2016: 112-21. PMID: 27570660, PMCID: PMC5001739, ISSN: 2153-4063.
Lovly CM, Salama AK, Salgia R. Tumor Heterogeneity and Therapeutic Resistance. Am Soc Clin Oncol Educ Book. 2016; 35: e585-93. PMID: 27249771, PII: 158808, DOI: 10.14694/EDBK_158808, ISSN: 1548-8756.
Giuse NB, Kusnoor SV, Koonce TY, Naylor HM, Chen SC, Blasingame MN, Anderson IA, Micheel CM, Levy MA, Ye F, Lovly CM. Guiding Oncology Patients Through the Maze of Precision Medicine. J Health Commun. 2016; 21 Suppl 1: 5-17. PMID: 27043753, PMCID: PMC4910693, DOI: 10.1080/10810730.2015.1131772, ISSN: 1087-0415.
Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J, Lovly CM. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Cancer Discov [print-electronic]. 2015 Nov; 5(11): 1155-63. PMID: 26286086, PMCID: PMC4631701, PII: 2159-8290.CD-15-0654, DOI: 10.1158/2159-8290.CD-15-0654, ISSN: 2159-8290.
Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. J. Clin. Oncol [print-electronic]. 2015 Oct 10/5/2015; PMID: 26438117, PII: JCO.2015.62.0138, DOI: 10.1200/JCO.2015.62.0138, ISSN: 1527-7755.
Iams WT, Lovly CM. Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade. Clin. Cancer Res. 2015 Oct 10/1/2015; 21(19): 4270-7. PMID: 26429980, PMCID: PMC4593065, PII: 21/19/4270, DOI: 10.1158/1078-0432.CCR-14-2518, ISSN: 1078-0432.
Iams WT, Lovly CM. Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. Cancer J. 2015 Sep; 21(5): 378-82. PMID: 26389762, PII: 00130404-201509000-00005, DOI: 10.1097/PPO.0000000000000142, ISSN: 1540-336X.
Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat. Med [print-electronic]. 2015 Sep; 21(9): 1038-47. PMID: 26301689, PII: nm.3930, DOI: 10.1038/nm.3930, ISSN: 1546-170X.
Ichihara E, Lovly CM. Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer. Cancer Discov. 2015 Jul; 5(7): 694-6. PMID: 26152920, PMCID: PMC4499857, PII: 5/7/694, DOI: 10.1158/2159-8290.CD-15-0616, ISSN: 2159-8290.
Meador CB, Lovly CM. Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors. Nat. Med. 2015 Jul; 21(7): 663-5. PMID: 26151324, PII: nm.3899, DOI: 10.1038/nm.3899, ISSN: 1546-170X.
Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin. Cancer Res. 2015 May 5/15/2015; 21(10): 2227-35. PMID: 25979929, PMCID: PMC4435823, PII: 21/10/2227, DOI: 10.1158/1078-0432.CCR-14-2791, ISSN: 1078-0432.
Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Cancer Immunol Res [print-electronic]. 2015 May; 3(5): 464-9. PMID: 25649350, PMCID: PMC4420706, PII: 2326-6066.CIR-14-0217, DOI: 10.1158/2326-6066.CIR-14-0217, ISSN: 2326-6074.
Hornick JL, Sholl LM, Dal Cin P, Childress MA, Lovly CM. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. Mod. Pathol [print-electronic]. 2015 May; 28(5): 732-9. PMID: 25612511, PII: modpathol2014165, DOI: 10.1038/modpathol.2014.165, ISSN: 1530-0285.
Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M. MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. Clin. Cancer Res [print-electronic]. 2015 Apr 4/15/2015; 21(8): 1935-43. PMID: 25351745, PMCID: PMC4401580, PII: 1078-0432.CCR-14-2124, DOI: 10.1158/1078-0432.CCR-14-2124, ISSN: 1078-0432.
Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res. 2015 Mar; 3(3): 288-95. PMID: 25736262, PMCID: PMC4351797, PII: 3/3/288, DOI: 10.1158/2326-6066.CIR-14-0207, ISSN: 2326-6074.
Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol. 2015 Mar; 10(3): 431-7. PMID: 25415430, PMCID: PMC4479120, DOI: 10.1097/JTO.0000000000000432, ISSN: 1556-1380.
Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, Lovly CM, Cross DA, Pao W. Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer. Mol. Cancer Ther [print-electronic]. 2015 Feb; 14(2): 542-52. PMID: 25477325, PMCID: PMC4338015, PII: 1535-7163.MCT-14-0723, DOI: 10.1158/1535-7163.MCT-14-0723, ISSN: 1538-8514.
Lovly CM. Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. Am Soc Clin Oncol Educ Book. 2015; e165-73. PMID: 25993168, PII: 0011500e165, DOI: 10.14694/EdBook_AM.2015.35.e165, ISSN: 1548-8756.
Yu HA, Riely GJ, Lovly CM. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin. Cancer Res [print-electronic]. 2014 Dec 12/1/2014; 20(23): 5898-907. PMID: 25303979, PMCID: PMC4253858, PII: 1078-0432.CCR-13-2437, DOI: 10.1158/1078-0432.CCR-13-2437, ISSN: 1078-0432.
Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. J Natl Compr Canc Netw. 2014 Nov; 12(11): 1629-49. PMID: 25361808, PII: 12/11/1629, ISSN: 1540-1413.
Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretic L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat. Med [print-electronic]. 2014 Sep; 20(9): 1027-34. PMID: 25173427, PMCID: PMC4159407, PII: nm.3667, DOI: 10.1038/nm.3667, ISSN: 1546-170X.
Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, Chung CT, Borinstein SC, Ross JS, Stephens PJ, Miller VA, Coffin CM. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov [print-electronic]. 2014 Aug; 4(8): 889-95. PMID: 24875859, PMCID: PMC4125481, PII: 2159-8290.CD-14-0377, DOI: 10.1158/2159-8290.CD-14-0377, ISSN: 2159-8290.
Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin. Cancer Res. 2014 May 5/1/2014; 20(9): 2249-56. PMID: 24789032, PMCID: PMC4029617, PII: 20/9/2249, DOI: 10.1158/1078-0432.CCR-13-1610, ISSN: 1078-0432.
Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin. Cancer Res [print-electronic]. 2014 May 5/1/2014; 20(9): 2264-75. PMID: 24599935, PMCID: PMC4008689, PII: 1078-0432.CCR-13-1591, DOI: 10.1158/1078-0432.CCR-13-1591, ISSN: 1078-0432.
Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretic L, Seidel D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M, Ansén S, Stoelben E, Wright GM, Russell P, Wainer Z, Solomon B, Field JK, Hyde R, Davies MP, Heukamp LC, Petersen I, Perner S, Lovly CM, Cappuzzo F, Travis WD, Wolf J, Vingron M, Brambilla E, Haas SA, Buettner R, Thomas RK. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun. 2014; 5: 3518. PMID: 24670920, PMCID: PMC4132974, PII: ncomms4518, DOI: 10.1038/ncomms4518, ISSN: 2041-1723.
Lammers PE, Lovly CM, Horn L. A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. J Natl Compr Canc Netw. 2014 Jan; 12(1): 6-11; quiz 11. PMID: 24453288, PMCID: PMC4151469, PII: 12/1/6, ISSN: 1540-1413.
Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA, Pao W. Characteristics of lung cancers harboring NRAS mutations. Clin. Cancer Res [print-electronic]. 2013 May 5/1/2013; 19(9): 2584-91. PMID: 23515407, PMCID: PMC3643999, PII: 1078-0432.CCR-12-3173, DOI: 10.1158/1078-0432.CCR-12-3173, ISSN: 1078-0432.
Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov [print-electronic]. 2013 Apr; 3(4): 430-43. PMID: 23533265, PMCID: PMC4086149, PII: 2159-8290.CD-12-0440, DOI: 10.1158/2159-8290.CD-12-0440, ISSN: 2159-8290.
Baikadi M, Lovly C, Horn L, Reckamp KL, Noonan K, Laskin J, Morris GJ. A 75-year-old man with progressive bronchioalveolar carcinoma. Semin. Oncol. 2013 Feb; 40(1): e1-8. PMID: 23391120, PII: S0093-7754(12)00203-5, DOI: 10.1053/j.seminoncol.2012.11.004, ISSN: 1532-8708.
Lovly CM, Horn L. Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC. Curr Treat Options Oncol. 2012 Dec; 13(4): 516-26. PMID: 22833206, DOI: 10.1007/s11864-012-0204-6, ISSN: 1534-6277.
Horn L, Lovly C. Update on HER1-3 in advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5): S369-71. PMID: 23160321, PII: 01243894-201212005-00003, DOI: 10.1097/JTO.0b013e31826defaa, ISSN: 1556-1380.
Levy MA, Lovly CM, Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res [print-electronic]. 2012 Nov; 22(11): 2101-8. PMID: 23019146, PMCID: PMC3483539, PII: gr.131128.111, DOI: 10.1101/gr.131128.111, ISSN: 1549-5469.
Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, Küppers R, Thomas RK. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin. Cancer Res [print-electronic]. 2012 Sep 9/1/2012; 18(17): 4682-90. PMID: 22912387, PII: 1078-0432.CCR-11-3260, DOI: 10.1158/1078-0432.CCR-11-3260, ISSN: 1078-0432.
Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol [print-electronic]. 2012 Mar 3/10/2012; 30(8): 863-70. PMID: 22215748, PMCID: PMC3295572, PII: JCO.2011.35.6345, DOI: 10.1200/JCO.2011.35.6345, ISSN: 1527-7755.
Lovly CM, Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med. 2012 Feb 2/8/2012; 4(120): 120ps2. PMID: 22323827, PII: 4/120/120ps2, DOI: 10.1126/scitranslmed.3003728, ISSN: 1946-6242.
Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate AJ, Sosman J, Pao W. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE [print-electronic]. 2012; 7(4): e35309. PMID: 22536370, PMCID: PMC3335021, PII: PONE-D-12-03589, DOI: 10.1371/journal.pone.0035309, ISSN: 1932-6203.
Heuckmann JM, Hölzel M, Sos ML, Heynck S, Balke-Want H, Koker M, Peifer M, Weiss J, Lovly CM, Grütter C, Rauh D, Pao W, Thomas RK. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin. Cancer Res [print-electronic]. 2011 Dec 12/1/2011; 17(23): 7394-401. PMID: 21948233, PMCID: PMC3382103, PII: 1078-0432.CCR-11-1648, DOI: 10.1158/1078-0432.CCR-11-1648, ISSN: 1078-0432.
Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res [print-electronic]. 2011 Jul 7/15/2011; 71(14): 4920-31. PMID: 21613408, PMCID: PMC3138877, PII: 0008-5472.CAN-10-3879, DOI: 10.1158/0008-5472.CAN-10-3879, ISSN: 1538-7445.
Lovly CM, Carbone DP. Lung cancer in 2010: One size does not fit all. Nat Rev Clin Oncol. 2011 Feb; 8(2): 68-70. PMID: 21278771, PII: nrclinonc.2010.224, DOI: 10.1038/nrclinonc.2010.224, ISSN: 1759-4782.
Lovly CM, Yan L, Ryan CE, Takada S, Piwnica-Worms H. Regulation of Chk2 ubiquitination and signaling through autophosphorylation of serine 379. Mol. Cell. Biol [print-electronic]. 2008 Oct; 28(19): 5874-85. PMID: 18644861, PMCID: PMC2547006, PII: MCB.00821-08, DOI: 10.1128/MCB.00821-08, ISSN: 1098-5549.
King JB, Gross J, Lovly CM, Piwnica-Worms H, Townsend RR. Identification of protein phosphorylation sites within Ser/Thr-rich cluster domains using site-directed mutagenesis and hybrid linear quadrupole ion trap Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun. Mass Spectrom. 2007; 21(21): 3443-51. PMID: 17918214, DOI: 10.1002/rcm.3223, ISSN: 0951-4198.
Bernal-Mizrachi L, Lovly CM, Ratner L. The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2006 Jun 6/13/2006; 103(24): 9220-5. PMID: 16751281, PMCID: PMC1482593, PII: 0507809103, DOI: 10.1073/pnas.0507809103, ISSN: 0027-8424.
King JB, Gross J, Lovly CM, Rohrs H, Piwnica-Worms H, Townsend RR. Accurate mass-driven analysis for the characterization of protein phosphorylation. Study of the human Chk2 protein kinase. Anal. Chem. 2006 Apr 4/1/2006; 78(7): 2171-81. PMID: 16579595, DOI: 10.1021/ac051520l, ISSN: 0003-2700.
Schwarz JK, Lovly CM, Piwnica-Worms H. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol. Cancer Res. 2003 Jun; 1(8): 598-609. PMID: 12805407, ISSN: 1541-7786.
Graves PR, Lovly CM, Uy GL, Piwnica-Worms H. Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene. 2001 Apr 4/5/2001; 20(15): 1839-51. PMID: 11313932, DOI: 10.1038/sj.onc.1204259, ISSN: 0950-9232.
Morgan SE, Lovly C, Pandita TK, Shiloh Y, Kastan MB. Fragments of ATM which have dominant-negative or complementing activity. Mol. Cell. Biol. 1997 Apr; 17(4): 2020-9. PMID: 9121450, PMCID: PMC232049, ISSN: 0270-7306.
Available Postdoctoral Position Details
Posted: 2/5/2018
We are accepting applications for a post-doctoral fellow position in the laboratory of Dr. Christine Lovly. The Lovly Lab specializes in translational lung cancer research, signal transduction, mechanisms of adaptive and acquired resistance to targeted therapies, genomics, and personalized structural biology. Recent work in the lab has been published in high impact journals, including Cancer Discovery and Nature Medicine. The Lovly lab is located within the Vanderbilt Ingram Cancer Center, which offers a dynamic, multidisciplinary environment with close interaction with other basic and clinical scientists. This is an ideal opportunity for a highly motivated and committed biologist to make an important contribution to understanding lung cancer biology. The Vanderbilt Ingram Cancer Center is located within Nashville, TN. Nashville, aka ‘Music City, offers a vibrant professional and personal setting, with thriving industries (music and health care) and a growing start-up scene. The city also offers excellent cost of living, professional sports, and great outdoor activities. We invite applications from individuals with: • An interest in translational lung cancer research • Exceptionally motivated, creative and committed to scientific discovery • Strong background and publication record in molecular and cellular biology, with experience in mammalian cell culture and murine studies
Please send a cover letter and CV to:
Christine Lovly, MD, PhD at christine.lovly@Vanderbilt.Edu